Universal Beteiligungs und Servicegesellschaft mbH Takes $12.37 Million Position in Glaukos Co. (NYSE:GKOS)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Glaukos Co. (NYSE:GKOS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 82,477 shares of the medical instruments supplier's stock, valued at approximately $12,367,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.15% of Glaukos at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Glaukos by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier's stock worth $895,887,000 after buying an additional 101,838 shares in the last quarter. Invesco Ltd. lifted its stake in Glaukos by 4.9% during the fourth quarter. Invesco Ltd. now owns 1,458,635 shares of the medical instruments supplier's stock worth $218,708,000 after purchasing an additional 68,310 shares during the last quarter. Geode Capital Management LLC lifted its stake in Glaukos by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 1,197,215 shares of the medical instruments supplier's stock worth $179,555,000 after purchasing an additional 25,199 shares during the last quarter. Gilder Gagnon Howe & Co. LLC lifted its stake in Glaukos by 25.3% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier's stock worth $123,742,000 after purchasing an additional 166,677 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Glaukos by 1,235.4% during the fourth quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock worth $122,374,000 after purchasing an additional 755,035 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos Trading Down 0.2%

NYSE GKOS traded down $0.23 on Tuesday, reaching $94.56. The company had a trading volume of 740,397 shares, compared to its average volume of 708,286. The firm has a market cap of $5.40 billion, a price-to-earnings ratio of -32.95 and a beta of 0.83. Glaukos Co. has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The business has a 50 day moving average of $92.26 and a two-hundred day moving average of $122.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. During the same period in the prior year, the business posted ($0.70) earnings per share. Glaukos's quarterly revenue was up 24.6% on a year-over-year basis. Analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 5.80% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on GKOS shares. Mizuho cut their target price on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Morgan Stanley cut their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Needham & Company LLC cut their target price on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Piper Sandler dropped their price target on Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research note on Tuesday, April 15th. Finally, Stifel Nicolaus dropped their price target on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $134.67.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.